A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration

Completed · Phase 1/Phase 2

Conditions studied: Age-related Macular Degeneration

In brief

The main purpose of this study to evaluate the safety and tolerability of CNTO 2476 administered subretinally (beneath the retina) using the iTrack Model 275 micro catheter in patients with visual acuity (acuteness or clearness of vision) impairment associated with the geographic atrophy (GA: partial or complete wasting away of retinal layer below the retina) manifestation of age-related macular degeneration (AMD: medical condition which usually affects older adults and results in a loss of vision in the center of the visual field \[the macula\] because of damage to the retina).

Key facts

Study ID
NCT01226628
Run by
Janssen Research & Development, LLC
People needed
39
Starts
2010-10-21
Expected to finish
2017-05-31
Last updated by the study team
2017-08-08

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.